Indo-Korean Pharma Linkages: A New Emerging Asian Front?
Executive Summary
Is there a new strategic Asian pharma partnership in the works? Early days perhaps but worth keeping an eye on the India-South Korea deal street.
You may also be interested in...
Deal Watch, Focus On Asia: Cipla Licenses India Rights To Lilly’s Basalgar
Cipla expands on its in-licensing strategy in India with Lilly’s insulin glargine product, while Aptose signs second agreement with CrystalGenomics to add Chinese rights for leukemia candidate CG-806, and Yakult gains Japanese rights to Verastem's duvelisib.
Deal Watch: BridgeBio To Launch New Subsidiary Around Rare Disease Candidate Obtained From Alexion
Sanofi completes the transition of its infectious disease unit to Evotec. Perhaps not yet done with virology, Gilead licenses technology for HIV/hep B vaccines from Hookipa.
Mission Fulphila - Mylan-Biocon Biosimilar Neulasta Takes The Stage In US
The first FDA-approved Neulasta biosimilar is here, opening up material earnings opportunities for partners Mylan and Biocon and affirming the duo's ability to deliver on their complex but high-value pipeline.